Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings

Introduction: Venetoclax (Ven) has changed the chronic lymphocytic leukemia (CLL) treatment landscape with the ability to produce deep responses that result in improved long-term outcomes with well-tolerated fixed-duration regimens. Due to its potent pro-apoptotic effect on CLL cells, Ven poses a ri...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2020-11, Vol.136 (Supplement 1), p.37-38
Hauptverfasser:	Seymour, John F., Gribben, John G., Davids, Matthew S., Mato, Anthony, Sharman, Jeff P, Cyr, Aimee, Bartkus, Cynthia, Pena, German, Boyer, Michelle, Sharmokh, Simon, Rosenberg, Tanya S, Wierda, William G.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!